ReviewNeuro-oncology advances2026
The molecular profile of gliomas in adolescents and young adults.
Review in Neuro-oncology advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurosurgical oncology at the crossroads of neurosurgery subspecialties: Intersections of sections.Neuro-oncology advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adolescents and young adults (AYAs), defined as individuals aged 15-39, represent a distinct and underrepresented population in glioma research and clinical care. Gliomas are the most common central nervous system (CNS) tumors in this population and span both pediatric and adult molecular subtypes, making diagnosis and treatment particularly complex. While the 2021 WHO classification of CNS tumors underscores key molecular differences across age groups, there remain limited standardized, age-specific guidelines for AYA patients. Molecular profiling is especially critical in this demographic, as more than 80% of AYA gliomas harbor potentially targetable alterations, including IDH mutations and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.